Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP

The peripheral T-cell lymphomas remain a therapeutic challenge because these aggressive cancers are both rare and extremely diverse. In fact, the most common peripheral T-cell lymphoma in Europe and North America is unspecified and remains a diagnosis of exclusion. CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) emerged as the standard of care in the treatment of aggressive non-Hodgkin lymphomas in the 1990s when the distinction between peripheral T-cell lymphoma and aggressive B-cell-derived non-Hodgkin lymphoma became apparent.